ArticlePloS one2016
Detection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Biomarkers in Primary Systemic Vasculitides: Narrative Review.International journal of molecular sciences · 2026Review
- Anti-pentraxin 3 antibodies and residual disease activity in rheumatoid arthritis.Rheumatology (Oxford, England) · 2025Article
- Biomarkers in ANCA associated vasculitis: clinical utility, pitfalls and their role in the outcomes assessment.Frontiers in immunology · 2025Review
- Childhood-Onset ANCA-Associated Vasculitis: From Genetic Studies to Advances in Pathogenesis, Classification and Novel Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Granulomatosis with polyangiitis: clinical characteristics and updates in diagnosis.Frontiers in medicine · 2024Review
- The eye is a common site of granulomatosis with polyangiitis. A collaborative study.BMC ophthalmology · 2023Article
- The crossroad between autoimmune disorder, tissue remodeling and cancer of the thyroid: The long pentraxin 3 (PTX3).Frontiers in endocrinology · 2023Review
- Unmet needs in ANCA-associated vasculitis: Physicians' and patients' perspectives.Frontiers in immunology · 2023Review
- Caspase-8 activation in neutrophils facilitates autoimmune kidney vasculitis through regulating CD4Frontiers in immunology · 2022Article
- Serological Biomarkers and Indices for the Current Activity and Prognosis of ANCA-Associated Vasculitis: Experience in a Single Centre in Korea.Yonsei medical journal · 2021Review
- Article
- Microparticles expressing myeloperoxidase as potential biomarkers in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV).Journal of molecular medicine (Berlin, Germany) · 2020Article
- ANCA-associated vasculitis.Nature reviews. Disease primers · 2020Review
- Anti-Pentraxin Antibodies in Autoimmune Diseases: Bystanders or Pathophysiological Actors?Frontiers in immunology · 2020Review
- Update on ANCA-associated vasculitis: from biomarkers to therapy.Journal of nephrology · 2019Review
- Clinico-pathological considerations in a 48-years-old female with acute kidney injury: is it lupus nephritis, ANCA-associated vasculitis or something else?BMC nephrology · 2019Article
- Biomarkers in Vasculitides of the Nervous System.Frontiers in neurology · 2019Review
- PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases.Frontiers in immunology · 2019Article
- Eosinophils from Physiology to Disease: A Comprehensive Review.BioMed research international · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPentraxin 3 (PTX3), in common with myeloperoxidase and proteinase 3, is stored in human neutrophil granules and is expressed on apoptotic neutrophil surface. We therefore investigated the presence of anti-PTX3 autoantibodies (aAbs) in the sera of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients.
methodsPresence of anti-PTX3 autoantibodies was analysed by a specific enzyme-linked immunosorbent assay in sera from 150 patients with microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA), and in sera of 227 healthy subjects (HS), 40 systemic sclerosis (SSc) patients, and 25 giant cell arteritis patients (GCA). Using indirect immunofluorescence on fixed human neutrophils, we also analyzed the staining pattern associated with the presence of anti-PTX3 aAbs.
resultsAnti-PTX3 aAbs were detected in 56 of 150 (37.3%) of the AAV patients (versus 12 of 227 (5.3%) of HS, p<0.001) and, interestingly, in 7 of 14 MPO and PR3 ANCA negative AAV patients. Moreover, by indirect immunofluorescence on fixed neutrophils, anti-PTX3 aAbs gave rise to a specific cytoplasmic fluorescence pattern distinct from the classical cytoplasmic (c-ANCA), perinuclear (p-ANCA), and atypical (a-ANCA) pattern. Anti-PTX3 aAbs levels were higher in patients with active AAV as compared to patients with inactive disease.
conclusionOur work suggests that PTX3 is as a novel ANCA antigen. Anti-PTX3 aAbs appear thus as a promising novel biomarker in the diagnosis of AAV, including in patients without detectable MPO and PR3 ANCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.